Global Immune Checkpoint Inhibitors Market to 2027 – Industry Size, Share & Trends Analysis Report

Dublin, April 26, 2022 (GLOBE NEWSWIRE) — The “Global Immune Checkpoint Inhibitor Market Size, Share & Trend Analysis Report by Application (Lung Cancer, Bladder Cancer, Melanoma, Hodgkin Lymphoma and Others), Type, Outlook and regional forecasts, 2021-2027″ report has been added to from ResearchAndMarkets.com offer.

The global immune checkpoint inhibitor market size is expected to reach USD 75.9 billion by 2027, growing at a market growth rate of 16.1% CAGR during the forecast period.

A checkpoint inhibitor is a kind of immunotherapy drug that works by blocking proteins on tumor cells that interfere with the activity of the immune system. CTLA-4 (cytotoxic T cell associated protein 4), PD-1 (programmed cell death protein 1) and PD-L1 are all immune checkpoint proteins that are blocked by immune checkpoint inhibitors (death programmed-ligand 1). Immune checkpoint inhibitors work by helping the immune system recognize and attack cancer cells by targeting checkpoint proteins.

Additionally, immune checkpoint inhibitors work by helping the immune system recognize and attack cancer cells by targeting checkpoint proteins. Due to an increase in demand for optimal therapies for cancer treatment, advantageous payment policies provided by manufacturers and insurers in some countries, and an increase in the incidence of cancer worldwide, the demand for immune checkpoint inhibitors is increasing.

COVID-19 Impact Analysis

The COVID-19 pandemic was first recorded in 2019 in China, after the first outbreak, the novel coronavirus quickly spread across the world and caused serious harm to people as well as businesses. Patients experience a variety of symptoms as a result of this infection, ranging from minor to severe. Dry cough, fever and exhaustion are some of the most common symptoms. Difficulty breathing or difficulty breathing, chest pain or pressure, and trouble speaking or moving are all dangerous signs. In addition, the virus has significant mortality potential in the geriatric population.

Additionally, COVID-19 has had an overall negative impact on the immune checkpoint inhibitor market, owing to a decrease in the number of cancer patients visiting hospitals and clinics for checkpoint inhibitor treatment checkpoint inhibitors (ICI), which has led to a decrease in demand for immune checkpoint inhibitors. immune checkpoint inhibitor products.

Market Growth Factors:

Increase in the prevalence of cancer worldwide

Lung cancer has a terrible prognosis and is the leading cause of cancer-related death worldwide. Both progression-free survival (PFS) and survival rate are limited despite vigorous treatment. Immune checkpoint inhibitors (ICI) targeting PD1, PDL1 and CTLA-4 are recently available for a variety of malignancies. ICI have transformed the treatment of cancer, including lung cancer, and made a huge breakthrough. However, there are many debates about whether patients are better treated with ICI in terms of monotherapy, combination therapy, and predictive biomarkers.

Immune checkpoint inhibitors have been shown to be effective in treating various cancers including breast, bladder, stomach, colon, liver, cervix, stomach , lung, skin, stomach and rectum.

Increase in the geriatric population in the world

The increasing prevalence of the geriatric population in the world is one of the major concerns of healthcare infrastructures globally. As a person’s age increases, their immune system is more vulnerable to various types of cancers, especially prostate cancer and lung cancer. The geriatric population is mostly more vulnerable to chronic diseases. According to data shared by the United Nations, in 2019, 703 million people aged 65 or over were registered worldwide. Moreover, this number is estimated at 1.5 billion by 2050 by the UN.

Marketing Restriction Factor:

Lack of people’s awareness

Cancer is a disease of different types, which can start in virtually any organ or tissue in the body and spread to other organs when abnormal cells grow out of control and invade surrounding areas of the body and/or move to other organs. It is a very deadly disease that can lead to loss of life. One of the main concerns of medical professionals around the world is that a large population is not fully aware of the prevalence of various types of cancer, which further delays diagnosis and therefore increases the rate. of mortality.

Main topics covered:

Chapter 1. Market Scope and Methodology
1.1 Market definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Immune Checkpoint Inhibitors Market, by Application
1.4.2 Global Immune Checkpoint Inhibitors Market, by Type
1.4.3 Global Immune Checkpoint Inhibitors Market, by Geography
1.5 Research Methodology

Chapter 2. Market Overview
2.1 Presentation
2.1.1 Presentation
2.1.1.1 Market composition and scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market constraints

Chapter 3. Competitive Analysis – Global
3.1 Cardinal matrix KBV
3.2 Recent Industry-Wide Strategic Developments
3.2.1 Partnerships, collaborations and agreements
3.2.2 Acquisitions and mergers
3.2.3 Approvals and tests
3.3 Main winning strategies
3.3.1 Key Primary Strategies: Percentage Breakdown (2017-2021)
3.3.2 Key Strategic Movement: (Partnerships, Collaborations and Agreements: 2017, May – 2021, December) Key Players

Chapter 4. Global Immune Checkpoint Inhibitors Market by Application
4.1 Global Lung Cancer Market by Region
4.2 Global Bladder Cancer Market by Region
4.3 Global Melanoma Market by Region
4.4 Global Hodgkin Lymphoma Market by Region
4.5 Global Other Application Market by Region

Chapter 5. Global Immune Checkpoint Inhibitors Market by Type
5.1 Global PD-1 Inhibitors Market by Region
5.2 Global PD-L1 Inhibitors Market by Region
5.3 Global CTLA-4 Inhibitor Market by Region

Chapter 6. Global Immune Checkpoint Inhibitors Market by Region

Chapter 7. Business Profiles
7.1 AstraZeneca PLC
7.1.1 Presentation of the company
7.1.2 Financial analysis
7.1.3 Regional Analysis
7.1.4 Research & Development expenses
7.1.5 Strategies and recent developments:
7.1.5.1 Partnerships, collaborations and agreements:
7.1.5.2 Approvals and tests:
7.2 Beigene Ltd.
7.2.1 Presentation of the company
7.2.2 Financial analysis
7.2.3 Regional Analysis
7.2.4 Research & Development expenses
7.2.5 Strategies and recent developments:
7.2.5.1 Partnerships, collaborations and agreements:
7.3 Shanghai Junshi Biosciences Co., Ltd.
7.3.1 Presentation of the company
7.3.2 Financial analysis
7.3.3 Research & Development expenses
7.4 Bristol Myers Squibb Company
7.4.1 Company overview
7.4.2 Financial analysis
7.4.3 Regional Analysis
7.4.4 Research & Development expenses
7.4.5 Strategies and recent developments:
7.4.5.1 Partnerships, collaborations and agreements:
7.4.5.2 Approvals and tests:
7.5 GlaxoSmithKline PLC (GSK)
7.5.1 Presentation of the company
7.5.2 Financial analysis
7.5.3 Sectoral and regional analysis
7.5.4 Research and development costs
7.6 Eli Lilly and company
7.6.1 Company Overview
7.6.2 Financial analysis
7.6.3 Regional Analysis
7.6.4 Research and development costs
7.7 Merck Group (Merck Sharp & Dohme Corp.)
7.7.1 Company Overview
7.7.2 Financial analysis
7.7.3 Sectoral and regional analysis
7.7.4 Research and development costs
7.7.5 Strategies and recent developments:
7.7.5.1 Partnerships, collaborations and agreements:
7.8 Sanofi SA
7.8.1 Company Overview
7.8.2 Financial analysis
7.8.3 Sectoral and regional analysis
7.8.4 Research and development costs
7.8.5 Strategies and recent developments:
7.8.5.1 Partnerships, collaborations and agreements:
7.8.5.2 Approvals and tests:
7.8.5.3 Acquisition and merger
7.9 Merck & Co., Inc.
7.9.1 Company Overview
7.9.2 Financial analysis
7.9.3 Sectoral and regional analysis
7.9.4 Research and development costs
7.9.5 Strategies and recent developments:
7.9.5.1 Partnerships, collaborations and agreements:
7.9.5.2 Approvals and tests:
7.10. F. Hoffmann-La Roche Ltd.
7.10.1 Company Overview
7.10.2 Financial analysis
7.10.3 Sectoral and regional analysis
7.10.4 Research and development costs
7.10.5 Strategies and recent developments:
7.10.6 Partnerships, Collaborations and Agreements:
7.10.6.1 Approvals and tests:

For more information on this report, visit https://www.researchandmarkets.com/r/qh2zje


CONTACT: ResearchAndMarkets.com
         Laura Wood, Senior Press Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900